BRPI0817007A2 - Proteína de ligação a antígeno isolada, molécula de ácido nucleico, vetor, célula hospedeira, métodos para preparar a proteína de ligação a antígeno, para tratar ou prevenir uma condição, para inibir a ligação de fator de estimulação de colônia de macrófago granulócito à porção extracelular de receptor de fator de estimulação de colônia de macrófago granulócito, e para inibir atividade de fator de estimulação de colônia de macrófago granulócito, e, composição farmacêutica - Google Patents

Proteína de ligação a antígeno isolada, molécula de ácido nucleico, vetor, célula hospedeira, métodos para preparar a proteína de ligação a antígeno, para tratar ou prevenir uma condição, para inibir a ligação de fator de estimulação de colônia de macrófago granulócito à porção extracelular de receptor de fator de estimulação de colônia de macrófago granulócito, e para inibir atividade de fator de estimulação de colônia de macrófago granulócito, e, composição farmacêutica

Info

Publication number: BRPI0817007A2
Authority: BR; Brazil
Prior art keywords: stimulating factor; colony stimulating; macrophage colony; granulocyte macrophage; binding protein
Prior art date: 2007-09-18

Application number

Other languages

English (en)

Inventor

Jacqueline A Kirchner

Kenneth A Brasel

Kara Olson

Jose Carlos Escobar

Dauphine Barone

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-09-18

Filing date

2008-09-18

Publication date

2015-03-24

2008-09-18 Application filed by Amgen Inc filed Critical Amgen Inc

2015-03-24 Publication of BRPI0817007A2 publication Critical patent/BRPI0817007A2/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Epidemiology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Optics & Photonics (AREA)
Mycology (AREA)
Orthopedic Medicine & Surgery (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)

BRPI0817007 2007-09-18 2008-09-18 Proteína de ligação a antígeno isolada, molécula de ácido nucleico, vetor, célula hospedeira, métodos para preparar a proteína de ligação a antígeno, para tratar ou prevenir uma condição, para inibir a ligação de fator de estimulação de colônia de macrófago granulócito à porção extracelular de receptor de fator de estimulação de colônia de macrófago granulócito, e para inibir atividade de fator de estimulação de colônia de macrófago granulócito, e, composição farmacêutica BRPI0817007A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US99434307P	2007-09-18	2007-09-18
US8755108P	2008-08-08	2008-08-08
PCT/US2008/010888 WO2009038760A2 (en)	2007-09-18	2008-09-18	Human gm-csf antigen binding proteins

Publications (1)

Publication Number	Publication Date
BRPI0817007A2 true BRPI0817007A2 (pt)	2015-03-24

Family

ID=40210593

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0817007 BRPI0817007A2 (pt)	2007-09-18	2008-09-18	Proteína de ligação a antígeno isolada, molécula de ácido nucleico, vetor, célula hospedeira, métodos para preparar a proteína de ligação a antígeno, para tratar ou prevenir uma condição, para inibir a ligação de fator de estimulação de colônia de macrófago granulócito à porção extracelular de receptor de fator de estimulação de colônia de macrófago granulócito, e para inibir atividade de fator de estimulação de colônia de macrófago granulócito, e, composição farmacêutica

Country Status (18)

Country	Link
US (3)	US8268311B2 (pt)
EP (2)	EP2236519A1 (pt)
JP (1)	JP2010538676A (pt)
KR (1)	KR101274356B1 (pt)
CN (1)	CN101861336A (pt)
AR (1)	AR066164A1 (pt)
AU (1)	AU2008302747B2 (pt)
BR (1)	BRPI0817007A2 (pt)
CA (1)	CA2698667C (pt)
CL (1)	CL2008002750A1 (pt)
CR (1)	CR11374A (pt)
EA (1)	EA201000490A1 (pt)
MX (1)	MX2010002968A (pt)
NZ (1)	NZ583787A (pt)
PE (1)	PE20091193A1 (pt)
TW (1)	TW200918553A (pt)
WO (1)	WO2009038760A2 (pt)
ZA (1)	ZA201002160B (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20110044996A1 (en) *	2007-05-23	2011-02-24	Charles Mackay	Neutralizing antibodies
AU2008323608A1 (en) *	2007-11-12	2009-05-22	Crc For Asthma And Airways Ltd	Epitope for neutralizing antibodies
RS52713B (sr)	2007-11-13	2013-08-30	Boehringer Ingelheim International Gmbh	Monoklonalna antitela koja se vezuju za hgm-csf i medicinske kompozicije koje sadrže iste
AU2009243184B2 (en)	2008-04-28	2015-06-04	Humanigen, Inc.	Antibodies to granulocyte-macrophage colony-stimulating factor
WO2010071923A1 (en)	2008-12-22	2010-07-01	The University Of Melbourne	Pain treatment
JP5727379B2 (ja)	2008-12-22	2015-06-03	ザユニバーシティーオブメルボルンＴｈｅＵｎｉｖｅｒｓｉｔｙｏｆＭｅｌｂｏｕｒｎｅ	変形性関節症の治療
US8609101B2 (en)	2009-04-23	2013-12-17	Theraclone Sciences, Inc.	Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies
JP2012530047A (ja) *	2009-05-05	2012-11-29	モルフォシス・アー・ゲー	多発性硬化症のための治療
US9567397B2 (en)	2010-11-18	2017-02-14	Merck Serono S.A.	Antibody with specificity for GM-CSF (I)
WO2012066089A1 (en) *	2010-11-18	2012-05-24	Merck Serono Sa	Antibody with specificity for gm-csf (ii)
EP2729498A1 (en)	2011-07-06	2014-05-14	MorphoSys AG	Therapeutic combinations of anti -cd20 and anti - gm - csf antibodies and uses thereof
WO2013090989A1 (en)	2011-12-22	2013-06-27	Csl Limited	Method of treating inflammatory bowel disease
CN104995210A (zh)	2012-09-20	2015-10-21	莫弗系统股份公司	类风湿关节炎的治疗
EP2914289B1 (en)	2012-10-31	2019-05-22	Takeda GmbH	Lyophilized formulation comprising gm-csf neutralizing compound
AR093297A1 (es)	2012-10-31	2015-05-27	Amgen Res Munich Gmbh	Formulacion liquida que comprende un compuesto neutralizante de gm-csf
EP3039039B1 (en)	2013-08-30	2021-03-10	Takeda GmbH	Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics
WO2015066262A1 (en) *	2013-11-04	2015-05-07	Trustees Of Dartmouth College	Methods for preventing toxicity of adoptive cell therapy
JP6769879B2 (ja) *	2014-05-07	2020-10-14	タケダ・ゲー・エム・ベー・ハーＴａｋｅｄａＧｍｂＨ	Ｇｍ−ｃｓｆ中和化合物を含む液体製剤
US11554181B2 (en)	2014-09-05	2023-01-17	The University Of North Carolina At Charlotte	Tumor specific antibody conjugates and uses therefor
KR102360824B1 (ko) *	2014-09-26	2022-02-09	내셔널 유니버시티 오브 싱가포르	Th-gm 세포 기능 조절 방법 및 조성물
JP6706617B2 (ja)	2014-11-06	2020-06-10	スカラーロックインコーポレイテッドＳｃｈｏｌａｒＲｏｃｋ，Ｉｎｃ．	抗プロ／潜在型−ミオスタチン抗体およびその使用
WO2016079276A1 (en) *	2014-11-21	2016-05-26	Takeda Gmbh	Use of an anti-gm-csf antagonist and an anti-ccr2 antagonist in the treatment of an infectious disease
WO2016079277A1 (en) *	2014-11-21	2016-05-26	Takeda Gmbh	Use of an anti-gm-csf antagonist in the treatment of an infectious disease
US10526404B2 (en)	2015-04-29	2020-01-07	Institute For Research In Biomedicine	Multispecific anti GM-CSF antibodies
JP2018527903A (ja) *	2015-07-22	2018-09-27	スカラーロックインコーポレイテッドＳｃｈｏｌａｒＲｏｃｋ，Ｉｎｃ．	Ｇｄｆ１１結合タンパク質およびその使用
SMT202500263T1 (it)	2015-09-15	2025-09-12	Scholar Rock Inc	Anticorpi anti-pro-miostatina/miostatina latente e loro usi
JP2019504064A (ja)	2016-01-08	2019-02-14	スカラーロックインコーポレイテッドＳｃｈｏｌａｒＲｏｃｋ，Ｉｎｃ．	抗プロ／潜在型ミオスタチン抗体およびその使用方法
NZ789268A (en)	2016-06-13	2026-01-30	Scholar Rock Inc	Use of myostatin inhibitors and combination therapies
EP3484499A4 (en)	2016-07-14	2020-05-13	Scholar Rock, Inc.	TGFB ANTIBODIES, METHODS AND USE
ES2887343T3 (es) *	2016-09-19	2021-12-22	I Mab Biopharma Hangzhou Co Ltd	Anticuerpos anti-GM-CSF y usos de los mismos
CN107840885B (zh) *	2016-09-19	2020-11-10	天境生物科技(上海)有限公司	Gm-csf抗体及其用途
AU2018205270B2 (en)	2017-01-06	2022-08-11	Scholar Rock, Inc.	Methods for treating metabolic diseases by inhibiting myostatin activation
JOP20190248A1 (ar) *	2017-04-21	2019-10-20	Amgen Inc	بروتينات ربط مولد ضد trem2 واستخداماته
US12025615B2 (en)	2017-09-15	2024-07-02	Arizona Board Of Regents On Behalf Of Arizona State University	Methods of classifying response to immunotherapy for cancer
US11655293B2 (en)	2018-02-22	2023-05-23	Universitat Zurich	Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
EP3623382A1 (en)	2018-09-14	2020-03-18	Universität Zürich	Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
WO2020092850A1 (en) *	2018-10-31	2020-05-07	Humanigen, Inc.	Materials and methods for treating cancer
WO2021045728A1 (en) *	2019-09-03	2021-03-11	The University Of North Carolina At Charlotte	Tumor specific antibody conjugates and uses therefor
EP4038222A4 (en)	2019-10-02	2023-10-18	Arizona Board of Regents on behalf of Arizona State University	Methods and compositions for identifying neoantigens for use in treating and preventing cancer
CA3173208A1 (en) *	2020-04-03	2021-10-07	Damien Bresson	Engineered antibodies that bind lag3
JP2020162622A (ja) *	2020-06-25	2020-10-08	インスティテュートフォーリサーチインバイオメディシン	多重特異性抗体によるサイトカインの非常に強力な中和およびその利用
EP4259284A4 (en) *	2020-12-10	2026-02-11	Univ Arizona State	CANINE CANCER VACCINE
WO2023200873A2 (en) *	2022-04-12	2023-10-19	Washington University	Chimeric antigen receptor compositions and methods of using the same
AU2023413166A1 (en)	2022-12-22	2025-07-03	Scholar Rock, Inc.	Selective and potent inhibitory antibodies of myostatin activation
CN117126277B (zh) *	2023-10-26	2024-01-23	中国科学院苏州纳米技术与纳米仿生研究所	一种单克隆抗体及其应用

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4263428A (en)	1978-03-24	1981-04-21	The Regents Of The University Of California	Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en)	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
EP0088046B1 (de)	1982-02-17	1987-12-09	Ciba-Geigy Ag	Lipide in wässriger Phase
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
HUT35524A (en)	1983-08-02	1985-07-29	Hoechst Ag	Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en)	1983-11-01	1988-10-12	TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION	Pharmaceutical composition containing urokinase
US4740461A (en)	1983-12-27	1988-04-26	Genetics Institute, Inc.	Vectors and methods for transformation of eucaryotic cells
US4751180A (en)	1985-03-28	1988-06-14	Chiron Corporation	Expression using fused genes providing for protein product
US4935233A (en)	1985-12-02	1990-06-19	G. D. Searle And Company	Covalently linked polypeptide cell modulators
WO1987005330A1 (en)	1986-03-07	1987-09-11	Michel Louis Eugene Bergh	Method for enhancing glycoprotein stability
US4959455A (en)	1986-07-14	1990-09-25	Genetics Institute, Inc.	Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
WO1988001649A1 (en)	1986-09-02	1988-03-10	Genex Corporation	Single polypeptide chain binding molecules
US5260203A (en)	1986-09-02	1993-11-09	Enzon, Inc.	Single polypeptide chain binding molecules
GB8624899D0 (en)	1986-10-17	1986-11-19	Sandoz Ltd	Monoclonal antibodies
US4912040A (en)	1986-11-14	1990-03-27	Genetics Institute, Inc.	Eucaryotic expression system
US5011912A (en)	1986-12-19	1991-04-30	Immunex Corporation	Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4965195A (en)	1987-10-26	1990-10-23	Immunex Corp.	Interleukin-7
US4968607A (en)	1987-11-25	1990-11-06	Immunex Corporation	Interleukin-1 receptors
US5070013A (en) *	1988-05-31	1991-12-03	Schering Corporation	Immunochemical assay for human granulocyte-macrophage colony stimulating factor
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
WO1990005183A1 (en)	1988-10-31	1990-05-17	Immunex Corporation	Interleukin-4 receptors
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
NZ234479A (en) *	1989-07-14	1992-03-26	Schering Corp	Antagonists of gm-csf derived from the carboxyl terminus, antibodies, hybridomas and pharmaceutical compositions containing anti-idiotypic antibodies
US5683888A (en)	1989-07-22	1997-11-04	University Of Wales College Of Medicine	Modified bioluminescent proteins and their use
US5292658A (en)	1989-12-29	1994-03-08	University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center	Cloning and expressions of Renilla luciferase
US6673986B1 (en)	1990-01-12	2004-01-06	Abgenix, Inc.	Generation of xenogeneic antibodies
US6713610B1 (en)	1990-01-12	2004-03-30	Raju Kucherlapati	Human antibodies derived from immunized xenomice
ES2284161T3 (es)	1990-01-12	2007-11-01	Amgen Fremont Inc.	Generacion de anticuerpos xenogenicos.
AU651596B2 (en)	1990-06-05	1994-07-28	Immunex Corporation	Type II interleukin-1 receptors
CA2089661C (en)	1990-08-29	2007-04-03	Nils Lonberg	Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en)	1990-08-29	2001-10-09	Genpharm International	Transgenic non-human animals for producing heterologous antibodies
US5874299A (en)	1990-08-29	1999-02-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en)	1990-08-29	1998-08-04	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en)	1990-08-29	2001-07-03	Genpharm International	High affinity human antibodies and human antibodies against digoxin
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5877397A (en)	1990-08-29	1999-03-02	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
CA2060741A1 (en) *	1991-02-11	1992-08-12	Robert S. Greenfield	Gm-csf inhibiting oligopeptides
ES2142801T3 (es)	1991-03-11	2000-05-01	Univ Georgia Res Found	Clonacion y expresion de luciferasa de renilla.
US6565841B1 (en)	1991-03-15	2003-05-20	Amgen, Inc.	Pulmonary administration of granulocyte colony stimulating factor
CA2111348A1 (en)	1991-06-14	1992-12-23	John S. Logan	Production of human hemoglobin in transgenic pigs
US5262522A (en)	1991-11-22	1993-11-16	Immunex Corporation	Receptor for oncostatin M and leukemia inhibitory factor
CA2124967C (en)	1991-12-17	2008-04-08	Nils Lonberg	Transgenic non-human animals capable of producing heterologous antibodies
WO1993015722A1 (en)	1992-02-07	1993-08-19	Syntex (Usa) Inc.	Controlled delivery of pharmaceuticals from preformed porous microparticles
ATE381614T1 (de)	1992-07-24	2008-01-15	Amgen Fremont Inc	Bildung von xenogenen antikörpern
WO1994010308A1 (en)	1992-10-23	1994-05-11	Immunex Corporation	Methods of preparing soluble, oligomeric proteins
US5457035A (en)	1993-07-23	1995-10-10	Immunex Corporation	Cytokine which is a ligand for OX40
US6146826A (en)	1993-09-10	2000-11-14	The Trustees Of Columbia University In The City Of New York	Green fluorescent protein
WO1995021191A1 (en)	1994-02-04	1995-08-10	William Ward	Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5777079A (en)	1994-11-10	1998-07-07	The Regents Of The University Of California	Modified green fluorescent proteins
EP0822830B1 (en)	1995-04-27	2008-04-02	Amgen Fremont Inc.	Human anti-IL-8 antibodies, derived from immunized xenomice
US5874304A (en)	1996-01-18	1999-02-23	University Of Florida Research Foundation, Inc.	Humanized green fluorescent protein genes and methods
AUPN780096A0 (en)	1996-01-30	1996-02-22	Medvet Science Pty. Ltd.	Cytokine antagonists and agonists
US5804387A (en)	1996-02-01	1998-09-08	The Board Of Trustees Of The Leland Stanford Junior University	FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en)	1996-02-06	1999-03-02	Bryan; Bruce	Bioluminescent novelty items
US5925558A (en)	1996-07-16	1999-07-20	The Regents Of The University Of California	Assays for protein kinases using fluorescent protein substrates
US5976796A (en)	1996-10-04	1999-11-02	Loma Linda University	Construction and expression of renilla luciferase and green fluorescent protein fusion genes
DE69738539T2 (de)	1996-12-03	2009-03-26	Amgen Fremont Inc.	Vollkommen humane Antikörper die EGFR binden
NZ335453A (en)	1996-12-12	2001-07-27	Prolume Ltd	Microelectronic device with microlocations including photodetector for detecting bioluminescence
CA2196496A1 (en)	1997-01-31	1998-07-31	Stephen William Watson Michnick	Protein fragment complementation assay for the detection of protein-protein interactions
US6342220B1 (en)	1997-08-25	2002-01-29	Genentech, Inc.	Agonist antibodies
US6232107B1 (en)	1998-03-27	2001-05-15	Bruce J. Bryan	Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
EP1105427A2 (en)	1998-08-17	2001-06-13	Abgenix, Inc.	Generation of modified molecules with increased serum half-lives
US7108852B2 (en) *	2000-03-20	2006-09-19	Warner-Lambert Company Llc	Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) *	2000-05-08	2008-11-25	The University Of Melbourne	Method of treatment and agents useful for same
ES2365606T3 (es) *	2002-02-13	2011-10-07	Ludwig Institute For Cancer Research Ltd.	Anticuerpos contra gm-csf quiméricos.
US7405275B2 (en) *	2003-09-24	2008-07-29	Millennium Pharmaceuticals, Inc.	Antibodies which bind human CXCR3
JP2007510622A (ja) *	2003-10-08	2007-04-26	ザ・フェインスタイン・インスティチュート・フォー・メディカル・リサーチ	Ｂ細胞慢性リンパ性白血病の診断及び治療のための方法及び組成物
DK1593690T3 (da) *	2004-05-05	2009-11-09	Micromet Ag	Fremstilling af ScFv-antistoffragmenter
BRPI0608281B8 (pt) *	2005-04-18	2021-05-25	Amgen Res Munich Gmbh	anticorpo monoclonal humano ou seu fragmento, seu uso no tratamento de doenças inflamatórias, bem como composição farmacêutica que o compreende
SI3620171T1 (sl) *	2005-05-18	2022-09-30	Morphosys Ag	Protitelesa proti GM-CSF in uporabe zanje
JP4736037B2 (ja) *	2005-10-26	2011-07-27	株式会社イーベック	ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
WO2007067991A2 (en) *	2005-12-08	2007-06-14	Medarex, Inc.	Human monoclonal antibodies to o8e
EP3181585A3 (en) *	2006-02-08	2017-08-30	Morphotek, Inc.	Antigenic gm-csf peptides and antibodies to gm-csf
BRPI0719109A2 (pt)	2006-11-21	2013-12-10	Kalobios Pharmaceuticals Inc	Métodos para tratar doenças inflamatórias crônicas usando um antagonista de gm-csf
AU2009243184B2 (en)	2008-04-28	2015-06-04	Humanigen, Inc.	Antibodies to granulocyte-macrophage colony-stimulating factor

2008
- 2008-09-08 TW TW097134377A patent/TW200918553A/zh unknown
- 2008-09-15 CL CL2008002750A patent/CL2008002750A1/es unknown
- 2008-09-17 PE PE2008001620A patent/PE20091193A1/es not_active Application Discontinuation
- 2008-09-18 US US12/675,013 patent/US8268311B2/en active Active
- 2008-09-18 CA CA2698667A patent/CA2698667C/en not_active Expired - Fee Related
- 2008-09-18 BR BRPI0817007 patent/BRPI0817007A2/pt not_active IP Right Cessation
- 2008-09-18 EP EP10166472A patent/EP2236519A1/en not_active Ceased
- 2008-09-18 KR KR1020107008307A patent/KR101274356B1/ko not_active Expired - Fee Related
- 2008-09-18 EP EP08832053A patent/EP2205636A2/en not_active Withdrawn
- 2008-09-18 WO PCT/US2008/010888 patent/WO2009038760A2/en not_active Ceased
- 2008-09-18 JP JP2010525835A patent/JP2010538676A/ja active Pending
- 2008-09-18 MX MX2010002968A patent/MX2010002968A/es active IP Right Grant
- 2008-09-18 EA EA201000490A patent/EA201000490A1/ru unknown
- 2008-09-18 NZ NZ583787A patent/NZ583787A/en not_active IP Right Cessation
- 2008-09-18 CN CN200880116214A patent/CN101861336A/zh active Pending
- 2008-09-18 AR ARP080104050A patent/AR066164A1/es not_active Application Discontinuation
- 2008-09-18 AU AU2008302747A patent/AU2008302747B2/en not_active Ceased
2010
- 2010-03-26 ZA ZA2010/02160A patent/ZA201002160B/en unknown
- 2010-04-15 CR CR11374A patent/CR11374A/es unknown
2012
- 2012-08-20 US US13/589,935 patent/US8481704B2/en active Active
2013
- 2013-06-11 US US13/914,905 patent/US20130259799A1/en not_active Abandoned

Also Published As

Publication number	Publication date
KR101274356B1 (ko)	2013-06-25
US20130071923A1 (en)	2013-03-21
AU2008302747A1 (en)	2009-03-26
EP2205636A2 (en)	2010-07-14
TW200918553A (en)	2009-05-01
AU2008302747B2 (en)	2012-02-02
CN101861336A (zh)	2010-10-13
CR11374A (es)	2010-05-19
US20130259799A1 (en)	2013-10-03
WO2009038760A3 (en)	2009-08-20
NZ583787A (en)	2012-05-25
MX2010002968A (es)	2010-06-15
PE20091193A1 (es)	2009-09-06
US8268311B2 (en)	2012-09-18
EP2236519A1 (en)	2010-10-06
AR066164A1 (es)	2009-07-29
CA2698667A1 (en)	2009-03-26
US20110189082A1 (en)	2011-08-04
WO2009038760A2 (en)	2009-03-26
CA2698667C (en)	2013-12-24
JP2010538676A (ja)	2010-12-16
CL2008002750A1 (es)	2009-02-06
KR20100059985A (ko)	2010-06-04
US8481704B2 (en)	2013-07-09
EA201000490A1 (ru)	2010-10-29
ZA201002160B (en)	2011-06-29

Publication	Publication Date	Title
BRPI0817007A2 (pt)	2015-03-24	Proteína de ligação a antígeno isolada, molécula de ácido nucleico, vetor, célula hospedeira, métodos para preparar a proteína de ligação a antígeno, para tratar ou prevenir uma condição, para inibir a ligação de fator de estimulação de colônia de macrófago granulócito à porção extracelular de receptor de fator de estimulação de colônia de macrófago granulócito, e para inibir atividade de fator de estimulação de colônia de macrófago granulócito, e, composição farmacêutica
BRPI0919377A2 (pt)	2016-09-27	anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
BRPI0920261A2 (pt)	2015-08-04	Composto, composição farmacêutica, uso do composto, e, método para inibir ou modular atividade de proteína quinase em uma amostra biológica
BRPI0810305A2 (pt)	2018-07-10	"vetor, molécula de ácido nucléico substancialmente isolada, célula hospedeira, composição farmacêutica, uso de uma molécula de ácido nucléico, uso de um vetor, uso de uma célula hospedeira e uso de uma composição"
BRPI0915105A2 (pt)	2019-09-24	composto de 2,4'-biripidinila como inibidores da proteína cinase d úteis para o tratamento de ia insuficiência cardíaca e cancer
BRPI0814781A2 (pt)	2014-10-21	Proteína, sequência de ácido nucleico, método para a produção de ácido itacônico, vetor, célula hospedeira, e, uso de um ácido cis-aconítico
BR112012022210A2 (pt)	2017-09-05	anticorpo isolado ou seu fragmento imunorreativo, molécula de ácido nucleico, composição farmacêutica, e, uso do anticorpo isolado
BR112013014708A2 (pt)	2016-10-04	composto, composição farmacêutica, e, método de inibir ou modular a atividade da cinase de proteína em uma amostra biológica
BRPI0916964A2 (pt)	2015-11-24	polipetídeo, anticorpo, ácido nucléico, vetor, célula hospedeira, método para produzir um polipeptídeo, composição e uso do polipeptídeo
BR112012024287A2 (pt)	2017-03-01	anticorpo, composição farmacêutica, método, ácido nucleico, vetor de expressão e célula hospedeira
BRPI0816014A8 (pt)	2018-06-19	anticorpo humano monoclonal isolado, composição, conjugado anticorpo-molécula parceiro, mólecula isolada de ácido nucléico, vetor de expressão, célula hospedeira, método para preparar um anticorpo anti-mesotelina, método de inibição do crescimento de uma célula tumoral expressando a mesotelina, método de tratamento do câncer em um indivíduo, anticorpo anti-mesotelina isolado, e método de inibir o crescimento de uma célula expressando a mesotelina
BRPI0922106A2 (pt)	2018-10-16	anticorpo monoclonal isolado, molécula de ácido nucleico isolada, célula hospedeira, método para produzir um anticorpo monoclonal isolado, composição farmacêutica, e, uso da composição
BRPI0822099A2 (pt)	2017-05-23	membro de ligação isolado, uso de um membro de ligação isolado, método parav tratar um distúrbio, molécula de ácido nucléico isolada, célula hospedeira, e, método para produzir um membro de ligação
BRPI0820552A2 (pt)	2014-10-14	Polipetídeo isolado, polinucleotídeo isolado, construção de ácido nucléico, vetor de expressão recombinante, célula hospedeira recombinante, métodos para produzir o polipeptídeo, para produzir uma proteína, e para degradar ou converter um material de biomassa, planta, parte vegetal ou célula vegetal transgêncica, método, composição, e. uso do polipeptídio.
BR112012006326A2 (pt)	2016-11-16	anticorpo biespecífico, composição farmacêutica, sequência de ácidos nucleicos, vetor de expressão, célula hospedeira procariótica ou eucariótica e invenção
BRPI0820647A2 (pt)	2014-11-04	Polipeptídeo isolado, polinucleotídeo isolado, construção de ácido nucleico, célula hospedeira recombinante, métodos para produzir o polipeptídeo e um mutante de uma célula percursora, célula mutante, planta transgênica, parte de planta ou célula de planta, molécula de rna inibidora de filamento duplo, e, métodos para inibir a expressão de um polipeptídeo um uma célula e para produzir uma proteína e para degradar um xilano
BRPI0913475A2 (pt)	2015-08-04	Molécula de ácido nucleico, vetor, célula, método para proteção de uma célula, métodos para expressão de uma proteína de interesse, método para adição ou intensificação da adaptabilidade ou resistência de uma célula e kit
BRPI1013807A2 (pt)	2019-09-24	composição, uso de uma composição, antagonista, sequência de polinucleotídeo, célula hospedeira recombinante transformada ou transfectada, método para a produção de uma composição, método para prevenir ou tratar um paciente, molécula de ligação de antígeno de marcação dual, e, proteína de ligação de antígeno.
BRPI0813242A2 (pt)	2015-08-18	Proteína de ligação a antígeno isolada, ácido nucléico isolado, vetor, célula hospedeira isolada, método para a produção de uma proteína de ligação a antígeno, e, composição.
BRPI0816117A2 (pt)	2015-03-10	Proteína de ligação de antígeno, anticorpo isolado, anticorpo de neutralização, composição farmacêutica, molécula de ácido nucléico, métodos para fabricar uma proteína de ligação de antígeno, para diminuir o nível de soro de colesterol em um paciente, para tratar ou prevenir uma condição, e, uso de uma proteína de ligação de antígeno.
FR2938760B1 (fr)	2012-08-17	Procede de maquillage de la peau et/ou des levres employant une compostion comprenant un polymere supramoleculaire, et composition cosmetique
IL213039A (en)	2015-03-31	Human anti-angiopoietin-2 antibodies, pharmacological compounds containing these antibodies, their nucleic acids encoded, and expression vectors
IL210485A (en)	2015-03-31	An isolated antibody or its functional protein, a process for making it, a pharmaceutical preparation containing it, and an isolated amino acid encoding an antibody or a functional protein
EP2175016A4 (en)	2012-03-28	ANTI-PROMININ-1 ANTIBODY WITH ADCC ACTIVITY OR CDC ACTIVITY
BRPI0905761A2 (pt)	2015-07-14	Anticorpo humanizado ou fragmento de ligação ao mesmo, ácido nucléico isolado, vetor, célula hospedeira, método para produzir um anticorpo humanizado ou o fragmento de ligação ao mesmo, composição, método para tratar uma doença ou distúrbio mediado por vwf em um indivíduo, uso de um anticorpo humanizado ou fragmento de ligação do mesmo, método para administração do anticorpo humanizado ou fragmento de ligação do mesmo, artigo de fabricação e kit

Legal Events

Date	Code	Title	Description
2015-12-01	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 7A ANUIDADE.
2016-04-05	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.